All Clarivate Analytics websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.

More information on our cookie policy.

BioWorld. Link to homepage.

/images/Cortellis_Flagship_Logo_TM_RGB_Color.png
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
  • Special reports
    • Artificial intelligence
    • Coronavirus
    • Diagnosing and tracking COVID-19
    • Drugs to Watch 2020
    • The next pandemic
    • Premium reports
      • BioWorld Financings Reports
      • Disease Forecast Reports

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Wednesday, March 3, 2021

Clinical

Home » Topics » Clinical
  • March 2, 2021
    By Elise Mak

    Ascletis joins Madrigal and Viking in global race for THR-β agonist for NASH

    Liver disease specialist Ascletis Pharma Inc. said its nonalcoholic steatohepatitis (NASH)-focused subsidiary, Gannex Pharma Co. Ltd., will start global development of its oral THR-β agonist, ASC-41, after it obtained an IND approval from the FDA based on positive phase I data generated in China.
  • Psychology disorders heads
    March 2, 2021
    By Randy Osborne

    Neurocrine schizophrenia thesis intact post-Interact? Opinions differ on phase II data

    San Diego-based Neurocrine Biosciences Inc.’s good-and-bad top-line phase II data with d-amino acid oxidase inhibitor luvadaxistat, also known NBI-1065844 and TAK-831, in schizophrenia likely came as little surprise to many, given earlier experience in the general pathway.
  • March 2, 2021

    In the clinic for March 2, 2021

    Clinical updates, including trial initiations, enrollment status and data readouts and publications: Aileron, Avadel, Biomx, Cerecor, Clearside, Gemoab, Highlight, Hoth, Inovio, Kymera, Eurocrine, Neurosense, NGM, Orbus, Pipeline, Scynexis, Seres.
Read More

Authors

  • Randy Osborne
  • Michael Fitzhugh
  • Lee Landenberger
  • Nuala Moran
  • Elise Mak
  • Mark McCarty
More Authors

Pages

  • Conference data of biopharma companies in 2021
  • Phase III clinical trial data of biopharma companies in 2021
  • Phase II clinical trial data of biopharma companies in 2021
  • Phase I clinical trial data of biopharma companies in 2021
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • About
    • Archives
    • Today's news
    • Search BioWorld Science
  • More
    • About
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
A Clarivate Analytic solution. Link to Clarivate website.
Follow Us

Copyright ©2021. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing